Brentie has posted a link to a post whose author believes that one one slot has been filled in the TNBC EAP in Salem, Oregon. This must be the result of too little information. So I took it upon myself to write to Oregon breast=cancer organizations, including Breast Friends, Pink Sistahs, and the Yew Club. (Haven't been able to find a good email address for the OHSU Knight Breast Cancer Institute, but they might already be involved.) Here's what I wrote, in case anyone wants to use it as a template in writing Breast-cancer organization anywhere.
(I realize some might think such letter-writing untoward. They might be right. But it might help, too.)
(I realize some might think such letter-writing untoward. They might be right. But it might help, too.)
Quote:I'm a former Portlander. I had a very dear friend who passed from triple-negative breast cancer. I'm writing to see if you would post information to the Yew Club about a Salem TNBC trial -- or disseminate the information in whatever way you can. I wrote to Breast Friends at the mail address, but not sure if that will reach a genuine person. (I'm not on Insta! Old person alert!)
I'm writing about a TNBC trial for a drug called Leronlimab, a monocolonal antibody. The trial is part of an expanded access program.
Here are some crucial facts:
1) The trial involves giving the patient Leronlimab; in the great majority of cases, this elevates PD-L1, which makes a checkpoint inhibitor like Keytruda a viable treatment option. In an earlier trial, six years ago, exactly five women were given this combination. All five had failed at least three earlier courses of treatment, and all five survive today, six years later. Four have no evidence of disease. So it's a good chance.
2) The trial is free of charge for the Leronlimab. Once the PD-L1 is sufficiently elevated, the patient's primary oncologist can then add an ICI, and patient insurance will pay for it.
3) The trial is being held in Salem.
4) Leronlimab has been given to over 1600 patients, most of them with crashed immunity systems, and yet there have been zero serious adverse events -- side effects. It is far safer than aspirin. It is not another round of grueling chemotherapy.
Patients must have metastatic or locally advanced TNBC and not have adequate treatment options available to them.
The way it works is this: most TNBC tumors are "cold" tumors, with few active immune cells. Leronlimab alters the tumor microenvironment so that it becomes "hot" -- and thus treatable. Leronlimab significantly increases PD-L1 expression on tumor cells in traditionally cold, resistant cancers.This effectively "ignites" the tumor, rendering it highly susceptible to Immune Checkpoint Inhibitors (like Keytruda) that previously would not work. When the PD-L1 is elevated (via Leronlimab), an ICI becomes the standard-of-care treatment, and works well.
Leronlimab blocks/occupies the CCR5 receptor, which is ubiquitous in the MOA of most solid-tumor cancers. Leronlimab has also been shown to drastically limit the traveling cancer cells that cause metastases.
Twenty slots are available for the trial, which has been funded by an anonymous (and thus mysterious) donor.
Here's contact info for the trial, from the clinicaltrials.gov site:
Study Contact
Name: Janet Brockus
Phone Number: 360-980-8524
Email: jbrockus@cytodyn.com
Study Contact Backup
Name: Joe Meidling
Phone Number: 360-980-8524
Email: jmeidling@cytodyn.com
I hope you can use this info to help some women in your network! This is a lethal disease that can literally be cured.
Yours with best -- Ken Glantz p.s. I can provide more info about Leronlimab if it helps. Here are some links for info and reference:
Clinicaltrials.gov link to the trial above:
https://clinicaltrials.gov/study/NCT07536815?...amp;rank=3
Leronlimab earlier trial results vs. msTNBC -- abstract published by Am. Association of Cancer Research, and poster presented there
> Abstract Feb. 2026
> https://aacrjournals.org/cancerimmunolres/art...-with-long
Poster
>> https://d1io3yog0oux5.cloudfront.net/_976f96f...evised.pdf
April 2026 abstract to AACR meeting:
> https://www.abstractsonline.com/pp8/#!/21436/...ation/9742
26
